Glasser Mark H, Zimmerman Joseph D
Department of Obstetrics and Gynecology, Kaiser Permanente Medical Center, San Rafael, California, USA.
J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):521-7. doi: 10.1016/s1074-3804(05)60160-0.
To assess the safety and efficacy of the HydroThermAblator (HTA) system to treat patients with menorrhagia and submucous myomas up to 4 cm in diameter.
Retrospective, multicenter, cohort study (Canadian Task Force classification II-2).
Two medical centers from a large, prepaid, multispecialty health maintenance organization.
Twenty-two women.
HTA endometrial ablation.
The HTA circulates free-flowing, heated (90 degrees C) saline in the uterine cavity for 10 minutes under direct hysteroscopic control. All procedures were performed in the office under local anesthesia after premedication with oral anxiolytic and analgesic agents. At least 1 year after treatment (average follow-up 15.4 mo, range 12-20 mo), women were contacted regarding their menstrual history. Success was defined as no additional medical or surgical intervention. Amenorrhea was defined as no bleeding, eumenorrhea as normal periods, and oligomenorrhea as less than a normal period. Twelve patients (54%) reported complete amenorrhea; 7 were premenopausal (41% amenorrhea rate) and 5 were postmenopausal (100% amenorrhea rate). Five (23%) reported oligomenorrhea and three (14%) eumenorrhea, and were very satisfied with the result. The overall success rate was 91%. Of two failures (9%), one woman had a repeat HTA 13 months later for menorrhagia. The other had a repeat HTA for persistent spotting and sustained a false passage and small perforation before the procedure began. She elected to have a vaginal hysterectomy 1 month later. Although the results are not statistically significant, patients were extremely satisfied with the outcomes, and no serious complications were related to the device or its use for this indication.
HTA is probably safe and effective in treating women with menorrhagia and submucous myomas up to 4 cm in diameter. It offers advantages over hysterectomy and electrosurgical resection since it is an office-based procedure, and significant advantages over other global ablation technologies that, by their design, are unable to treat significantly distorted uterine cavities.
评估热消融仪(HTA)系统治疗月经过多和直径达4厘米的黏膜下肌瘤患者的安全性和有效性。
回顾性、多中心队列研究(加拿大工作组分类II-2)。
来自一个大型的、预付费的、多专科健康维护组织的两家医疗中心。
22名女性。
HTA子宫内膜消融术。
HTA在直接宫腔镜控制下,使90摄氏度的自由流动热盐水在宫腔内循环10分钟。所有手术均在口服抗焦虑和镇痛药物进行预处理后,于门诊在局部麻醉下进行。治疗后至少1年(平均随访15.4个月,范围12 - 20个月),与患者联系询问月经史。成功定义为无需额外的药物或手术干预。闭经定义为无出血,月经过多定义为月经正常,月经过少定义为少于正常月经量。12名患者(54%)报告完全闭经;7名处于绝经前(闭经率41%),5名处于绝经后(闭经率100%)。5名(23%)报告月经过少,3名(14%)报告月经正常,她们对结果非常满意。总体成功率为91%。在两名失败患者(9%)中,一名女性在13个月后因月经过多再次接受HTA治疗。另一名因持续性点滴出血再次接受HTA治疗,在手术开始前出现假道和小穿孔。她在1个月后选择进行阴道子宫切除术。尽管结果无统计学意义,但患者对治疗结果非常满意,且未出现与该设备或其用于此适应症相关的严重并发症。
HTA治疗月经过多和直径达4厘米的黏膜下肌瘤女性患者可能是安全有效的。与子宫切除术和电外科切除术相比,它具有优势,因为它是一种门诊手术,并且与其他因设计原因无法治疗严重变形子宫腔的整体消融技术相比具有显著优势。